• Innoviva disclosed board resignations from Derek Small and Mark DiPaolo on May 12, 2026, as both shift focus to Syndeio BioSciences, where Small is CEO and DiPaolo is expected to take an executive role.
• The company flagged continued support for Syndeio, describing it as a key platform for therapies targeting neuropsychiatric and related disorders.
• Josephine Linden joined the board on May 18, 2026; she founded Linden Global Strategies, previously served as an adjunct professor at Columbia Business School, and retired from Goldman Sachs as a partner and managing director.
• Linden is expected to join the audit committee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innoviva Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-228958), on May 18, 2026, and is solely responsible for the information contained therein.